Emily. J. Miller. - FDA {@FDASpox} (2020) Convalescent plasma has shown to be beneficial for 35% of patients. This risk reduction figure - shown in chart below - is from @MayoClinic data from expanded access program that was analyzed by FDAA for the emergency use authorization announced today. Twitter. Retrieved from: https://twitter.com/FDASpox/status/1297706985039835136

The New York Times (2020) C.D.C. Halts Evictions, Citing Covid-19 Risks. Retrieved from: https://www.nytimes.com/2020/09/01/world/covid-19-coronavirus.html?action=click&module=Top%20Stories&pgtype=Homepage#link-26bc7ab3

Kominers, S. D., Pathak, P. A., Sönmez, T., & Ünver, M. U. (2020). Paying It Backward and Forward: Expanding Access to Convalescent Plasma Therapy Through Market Design (Working Paper No. 27143; Working Paper Series). National Bureau of Economic Research. https://doi.org/10.3386/w27143

Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R. L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., Li, X., Xi, Y., Chen, R., Alshukairi, A. N., Chen, Z., Zhang, Z., Chen, C., Huang, X., Li, F., … Zhao, J. (2020). Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. https://doi.org/10.1016/j.cell.2020.06.010

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619